12 results on '"Schubiger, P. August"'
Search Results
2. Silver(I) complexes of the derivatized crown thioether ligands 3,6,9,12,15,18-hexathianonadecanol and 3,6,9,13,16,19-hexathiaicosanol. Determination of stability constants and the crystal structures of (Ag(19-aneS6-OH))(CF3SO3) and (Ag(20-aneS6-OH))(BF4)
- Author
-
Alberto, Roger, Nef, Walter, Smith, Alan, Kaden, Thomas A., Neuburger, Markus, Zehnder, Margareta, Frey, Alfred, Abram, Ulrich, and Schubiger, P. August
- Subjects
Silver compounds -- Research ,Crown ethers -- Analysis ,Molecular structure -- Analysis ,Ring formation (Chemistry) -- Usage ,Chemistry - Abstract
The derivatized crown thioethers 3,6,9,12,15,18-hexathianonadecanol (19-aneS6-OH) and 3,6,9,13,16,19-hexathiacycloicosanol (20-aneS6-OH) are prepared by (1 + 1) cyclization and used as ligands for synthesizing silver(I) complexes. The silver complex cations (Ag(19-aneS6-OH))+ and (Ag(20-aneS6-OH))+ reside in a distorted tetrahedral coordination geometry. The complex cations have identical solution structures but different solid structures. Stability constants for the silver complexes in methanol are estimated.
- Published
- 1996
3. Versatile routes to C-2- and C-6-functionalized glucose derivatives of iminodiacetic acid
- Author
-
Dumas, Cecile, Schibli, Roger, and Schubiger, P. August
- Subjects
Chemistry, Organic -- Research ,Schiff bases ,Chemical reactions -- Analysis ,Acids -- Composition ,Transition metals -- Composition ,Biological sciences ,Chemistry - Abstract
Research has been conducted on D-glucose derivatives. The preparation of these compounds which have been functionalized at C-2/C-6 position with iminodiacetic acid for the transition-metal complexation is described.
- Published
- 2003
4. Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.
- Author
-
Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, and Dinkelborg LM
- Subjects
- Animals, Chemistry Techniques, Synthetic, Fluorine Radioisotopes, Humans, Matrix Metalloproteinase Inhibitors chemistry, Matrix Metalloproteinase Inhibitors pharmacology, Mice, Mice, Inbred C57BL, Drug Design, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 9 metabolism, Matrix Metalloproteinase Inhibitors chemical synthesis, Multimodal Imaging methods, Positron-Emission Tomography, Tomography, X-Ray Computed
- Abstract
The activity of matrix metalloproteinases (MMPs) is elevated locally under many pathological conditions. Gelatinases MMP2 and MMP9 are of particular interest because of their implication in angiogenesis, cancer cell proliferation and metastasis, and atherosclerotic plaque rupture. The aim of this study was to identify and develop a selective gelatinase inhibitor for imaging active MMP2/MMP9 in vivo. We synthesized a series of N-sulfonylamino acid derivatives with low to high nanomolar inhibitory potencies. (R)-2-(4-(4-Fluorobenzamido)phenylsulfonamido)-3-(1H-indol-3-yl)propanoic acid (7) exhibited the best in vitro binding properties: MMP2 IC50 = 1.8 nM, MMP9 IC50 = 7.2 nM. Radiolabeling of 7 with no carrier added (18)F-radioisotope was accomplished starting from iodonium salts as precursors. The radiochemical yield strongly depended on the iodonium counteranion (ClO4(-) > Br(-) > TFA(-) > tosylate). (18)F-7 was obtained in up to 20% radiochemical yield (decay corrected), high radiochemical purity, and >90 GBq/μmol specific radioactivity. The radiolabeled compound showed excellent stability in vitro and in mice in vivo.
- Published
- 2013
- Full Text
- View/download PDF
5. 4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization.
- Author
-
Krasikova RN, Kuznetsova OF, Fedorova OS, Belokon YN, Maleev VI, Mu L, Ametamey S, Schubiger PA, Friebe M, Berndt M, Koglin N, Mueller A, Graham K, Lehmann L, and Dinkelborg LM
- Subjects
- Cell Line, Tumor, Fluorine Radioisotopes, Glutamates chemistry, Glutamates metabolism, Humans, Isotope Labeling, Positron-Emission Tomography, Radiopharmaceuticals chemistry, Radiopharmaceuticals metabolism, Stereoisomerism, Glutamates chemical synthesis, Radiopharmaceuticals chemical synthesis
- Abstract
There is a high demand for tumor specific PET tracers in oncology imaging. Besides glucose, certain amino acids also serve as energy sources and anabolic precursors for tumors. Therefore, (18)F-labeled amino acids are interesting probes for tumor specific PET imaging. As glutamine and glutamate play a key role in the adapted intermediary metabolism of tumors, the radiosynthesis of 4-[(18)F]fluoro l-glutamic acid (BAY 85-8050) as a new specific PET tracer was established. Cell-uptake studies revealed specific tumor cell accumulation.
- Published
- 2011
- Full Text
- View/download PDF
6. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
- Author
-
Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schubiger PA, Schibli R, and García Garayoa E
- Subjects
- Animals, Bombesin analogs & derivatives, Bombesin pharmacokinetics, Cattle, Cell Line, Tumor, Chelating Agents chemistry, Costs and Cost Analysis, Gene Expression Regulation, Neoplastic, Glycosylation, Humans, Mice, Neoplasms diagnostic imaging, Neoplasms pathology, Protein Binding, Radiometry, Receptors, Bombesin analysis, Sensitivity and Specificity, Staining and Labeling, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Bombesin chemistry, Bombesin metabolism, Neoplasms metabolism, Organotechnetium Compounds chemistry, Receptors, Bombesin metabolism
- Abstract
Radiolabeled bombesin (BBS) analogues are promising pharmaceuticals for imaging of cancer cells expressing gastrin-releasing peptide receptors (GRPR). However, most of the radiolabeled BBS derivatives show a high accumulation of activity in the liver and a strong hepatobiliary excretion, both unfavorable for imaging and therapy of abdominal lesions. For this reason, we introduced hydrophilic carbohydrated linker moieties into our BBS analogues to reduce the abdominal accumulation and to improve the tumor-to-background ratios. A stabilized BBS(7-14) sequence bearing the (NalphaHis)Ac-chelator was modified with amino acid linkers containing a lysine or propargylglycine residue. The epsilon-amino group of a lysine was either coupled to shikimic acid or reacted with glucose to form the Amadori conjugate. Alternatively, a glucose was attached to the peptide via "click" chemistry with the propargylglycine side chain. The peptides were synthesized on Rink amide resin using solid-phase peptide synthesis and labeled with 99mTc using the tricarbonyl technique. Binding and degradation were tested in Vitro in GRPR-expressing PC-3 cells. Biodistribution and SPECT/CT imaging studies were performed in nude mice bearing PC-3 tumor xenografts. The new peptides showed a log D between -0.2 and -0.5 and kept the high affinity for GRPR with Kd values of <0.5 nM. In Vitro, they were rapidly internalized into the tumor cells and showed an increased cellular retention and stability (t(1/2 )>35 min). In ViVo, all new compounds exhibited higher tumor-to-background ratios compared to the nonglycated reference. Thus, the best results were obtained with the triazole coupled glucose with a 4-fold increased uptake and retention in tumor tissue (3.6 and 2.5%ID/g at 1.5 h and 5 h p.i, respectively) and a significantly reduced accumulation in the liver (0.6 vs 2.4%ID/g, 1.5 h p.i., respectively). Apart from higher tumor-to-liver ratios (17-fold, 1.5 h p.i.), both tumor-to-kidney and tumor-to-blood ratios could be significantly improved by a factor of 1.5 and 2.7, respectively (1.5 h p.i., P<0.05). The imaging studies proved the reduction of abdominal background, and tumor xenografts could clearly be visualized. In conclusion, the introduction of a carbohydrated linker substantially improved the biodistribution properties of BBS analogues labeled with the 99mTc-tricarbonyl core.
- Published
- 2008
- Full Text
- View/download PDF
7. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
- Author
-
Ross TL, Honer M, Lam PY, Mindt TL, Groehn V, Schibli R, Schubiger PA, and Ametamey SM
- Subjects
- Animals, Carrier Proteins metabolism, Drug Evaluation, Preclinical, Folate Receptors, GPI-Anchored, Humans, KB Cells, Male, Mice, Microsomes, Liver metabolism, Positron-Emission Tomography, Radiochemistry, Radiopharmaceuticals pharmacokinetics, Receptors, Cell Surface metabolism, Staining and Labeling, Stereoisomerism, Substrate Specificity, Tissue Distribution, Fluorine Radioisotopes chemistry, Folic Acid chemistry, Radiopharmaceuticals chemistry, Radiopharmaceuticals metabolism
- Abstract
The folate receptor (FR) is highly expressed on most epithelial cancer cells, while normal cells show only restricted expression of FR. As a result, the FR is an ideal target for receptor-based molecular imaging and therapy of cancer and has become a promising target in oncology. To date, several folate-based chemotherapeutics and imaging probes such as radiopharmaceuticals for single photon emission computed tomography (SPECT) have been developed. However, an (18)F-labeled folic acid derivative suitable for positron emission tomography (PET) imaging that can be routinely applied is still lacking. In this study, a new fluorinated and radiofluorinated folic acid derivative, (18/19)F-click folate, was synthesized using click chemistry. In a convenient and very efficient two-step radiosynthesis, the isolated (18)F-click folate was obtained in good radiochemical yields of 25-35% with a specific activity of 160+/-70 GBq/micromol after
- Published
- 2008
- Full Text
- View/download PDF
8. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core.
- Author
-
García Garayoa E, Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwe DA, Schibli R, and Schubiger PA
- Subjects
- Animals, Bombesin chemical synthesis, Bombesin metabolism, Cell Line, Tumor, Female, Humans, Mice, Octanols chemistry, Staining and Labeling, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Water chemistry, Bombesin chemistry, Bombesin pharmacokinetics, Organotechnetium Compounds chemistry
- Abstract
The overexpression of Bombesin (BBS) receptors on a variety of human cancers make them interesting targets for tumor imaging and therapy. Analogues of the neuropeptide BBS have been functionalized with the (NalphaHis)- chelator for labeling with the 99mTc-tricarbonyl core. The introduction of a betaAla-betaAla linker between the stabilized BBS binding sequence and the chelator led to increased tumor uptake but still rather unfavorable in ViVo properties. Novel polar linkers, with different charge, have been introduced in the molecule and tested for their influence on the biodistribution. The new analogues showed a shift in hydrophilicity from a Log D=0.9 to Log D values between 0.4 and -2.2. All compounds kept the increased stability in both human plasma (t(1/2)>16 h) and in tumor cells (t(1/2)=30-40 min). The compounds with Log D values between +1 and -1 showed the highest binding affinities with Kd values of <0.5 nM, as well as the highest cellular uptake. However, higher hydrophilicity (Log D < -1.8) led to lower affinity and a substantial decrease of internalization. The introduction of a positive charge (beta3hLys) resulted in unfavorable biodistribution, with increased kidney uptake. The introduction of an uncharged hydroxyl group (beta3hSer) improved the biodistribution, resulting in significantly better tumor-to-tissue ratios. The compound with one single negative charge (beta3hGlu) showed a significant increase in the tumor uptake (2.1+/-0.6% vs 0.80+/-0.35% ID/g in comparison to the betaAla-betaAla analogue) and also significantly higher tumor-to-tissue ratios. The specificity of the in ViVo uptake was confirmed by coinjection with natural BBS. Moreover, the analogue provided a much clearer image of the tumor xenografts in the SPECT/CT studies. The introduction of a single negative charge may be useful in the development of new BBS analogues to obtain an improved biodistribution profile, with increased tumor uptake and better imaging.
- Published
- 2008
- Full Text
- View/download PDF
9. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.
- Author
-
Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, and Srinivasan A
- Subjects
- Amino Acid Sequence, Binding Sites, Bombesin analogs & derivatives, Humans, Isotope Labeling, Male, Molecular Sequence Data, Prostatic Neoplasms metabolism, Silicon metabolism, Substrate Specificity, Bombesin chemical synthesis, Fluorine Radioisotopes chemistry, Neurotransmitter Agents chemical synthesis, Positron-Emission Tomography methods, Prostatic Neoplasms pathology, Receptors, Bombesin metabolism, Silicon chemistry
- Abstract
The gastrin-releasing peptide receptor (GRPr) is overexpressed on various human tumors. The goal of our study was the synthesis of new 18F-labeled bombesin analogues for the PET imaging of GRPr expression in prostate tumor using a silicon-based one-step n. c. a. radiolabeling method. The silicon-containing building blocks were efficiently coupled to the N-terminus of the peptides via solid-phase synthesis. Radiolabeling of the obtained peptide precursors proceeded smoothly under acidic conditions (34-85% conversion). Using the di-tert-butyl silyl building block as labeling moiety, products containing a hydrolytically stable 18F-label were obtained. In in vitro receptor binding experiments 2-(4-(di-tert-butylfluorosilyl)phenyl)acetyl-Arg-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH 2 ( 4b, IC50 = 22.9 nM) displayed a 12-fold higher binding affinity than 2-(4-(di-tert-butylfluorosilyl)phenyl)acetyl-Arg-Ava-Gln-Trp-Ala-Val-Gly-His(3Me)-Sta-Leu-NH2 ( 3b, IC50 = 276.6 nM), and 4b was therefore chosen for further evaluation. In vitro and ex vivo metabolite studies of [18F]4b showed no significant degradation. In biodistribution experiments, tumor uptake of [18F]4b was low and unspecific, whereas the GRPr-rich pancreas revealed a high and specific accumulation of the radiotracer. This study demonstrates the applicability of our silicon-based one-step n. c. a. radiolabeling method for the synthesis of new 18F-labeled bombesin derivatives. This innovative approach represents a general, straightforward access to radiolabeled peptides as PET imaging probes.
- Published
- 2008
- Full Text
- View/download PDF
10. Synthesis and in vitro/in vivo evaluation of novel 99mTc(CO)3-folates.
- Author
-
Müller C, Schubiger PA, and Schibli R
- Subjects
- Animals, Chromatography, High Pressure Liquid, Female, Folic Acid chemical synthesis, Folic Acid pharmacokinetics, Humans, KB Cells, Mice, Mice, Nude, Molecular Structure, Technetium Compounds chemistry, Technetium Compounds pharmacokinetics, Carbon Monoxide chemistry, Folic Acid chemistry, Folic Acid pharmacology, Technetium Compounds chemical synthesis, Technetium Compounds pharmacology
- Abstract
Novel organometallic 99mTc(I)-folate derivatives have been synthesized and evaluated in vitro and in vivo in order to assess the influence of the overall charge of the radioconjugates and the spacer entity on the affinity and pharmacokinetic profile. Folic acid has been functionalized at the gamma-carboxylate group of the glutamate moiety with (i) a hydrophilic diethoxyethyl spacer bearing a picolylamine monoacetic acid chelate, (ii) a hexyl spacer bearing an iminodiacetic acid chelate, and (iii) a hexyl spacer with a bis(pyridylmethyl)amine chelating system. Coordination of the 99mTc(CO)3-core resulted in neutral complex 21, anionic complex 22, and cationic complex 23 in excellent yields (>90%) at ligand concentrations of 10(-4) M. Complexes 21-23 were HPLC purified for in vitro and in vivo experiments. In the case of 23, separation from the unlabeled folate analogue was incomplete, leading to low specific activity and, hence, significantly inferior in vivo uptake in folate-receptor-positive (FR-positive) organs and tissues (tumors and kidneys). Time dependent in vivo studies were performed in female, athymic nude mice bearing subcutaneous FR-positive human KB cell xenografts at 1, 4, and 24 h post injection (p.i.) of the radiotracers. Tumor uptake ranged between 1.9-2.7% ID/g, 4 h p.i. and 1.6-2.2% ID/g, 24 h p.i. for 21 and 22, and 0.9% ID/g, 4 h p.i. and 1.1% ID/g, 24 h p.i. for 23. Blood clearance was fast for all derivatives (< or =0.2% ID/g 1 h p.i.). Significant fractions of radioactivity were found in nontargeted and FR-negative organs and tissues (particularly in the liver and the intestines/intestinal contents) at early time points p.i. Coadministration of folic acid reduced radioactivity in FR-positive tissues and organs to background levels. In conclusion, overall charge and the nature of the spacer entity seemed to have a relatively minor influence on receptor affinity and the in vivo pharmacokinetic profile of the tested radiofolates.
- Published
- 2006
- Full Text
- View/download PDF
11. Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase.
- Author
-
Schibli R, Dumas C, Petrig J, Spadola L, Scapozza L, Garcia-Garayoa E, and Schubiger PA
- Subjects
- Binding, Competitive, Cell Line, Tumor, Chelating Agents chemistry, Colonic Neoplasms metabolism, Drug Stability, Fungal Proteins chemistry, Glucose Transporter Type 1, Humans, Ligands, Models, Chemical, Organotechnetium Compounds pharmacology, Radiopharmaceuticals pharmacology, Technetium Tc 99m Exametazime chemistry, Glucose chemistry, Hexokinase metabolism, Monosaccharide Transport Proteins metabolism, Organotechnetium Compounds chemical synthesis, Radiopharmaceuticals chemical synthesis, Rhenium chemistry
- Abstract
A series of nine organometallic technetium-99m and rhenium complexes of glucose are presented and characterized in vitro regarding their potential as surrogates of [18F]-2-fluoro-desoxy glucose ([18F]-FDG). The glucose derivatives are functionalized at positions C-1, C-2, C-3, and C-6. Different spacer lengths and chelating systems have been introduced at these sites. For the (radio)labeling, the organometallic precursors [99mTc(H2O)3(CO)3]+ and [ReBr3(CO)3](2-) respectively have been used. The resulting complexes have been characterized chemically and radiochemically. The formation of uniform products has been observed on the macroscopic (Re) and no-carrier-added level (99mTc). The Tc-99m complexes revealed good inertness against ligand exchange (Cys and His) and excellent stability in physiological buffered saline as well as in human plasma over a period of 24 h at 37 degrees C. The rhenium complexes have been tested for competitive inhibition of the (yeast) hexokinase. Only for C-2 derivatized glucose complexes with extended spacer functionalities Ki values in the millimolar and sub-millimolar range have been observed. In silico molecular docking experiments supported these experimental findings. However, the competitive inhibitors are not recognized as a pseudosubstrate of hexokinase. The cellular uptake of all 99mTc-complexes into HT-29 colon carcinoma cells via Glut1 was generally low and unspecific independent of the position at the hexose ring, the chelating systems, or the overall charge of the corresponding metal complexes. The current results seem to preclude the use of these compounds as [18F]-FDG surrogates primarily due to the low cellular uptake via Glut1.
- Published
- 2005
- Full Text
- View/download PDF
12. Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor [(188)Re(H(2)O)(3)(CO)(3)](+) and synthesis of tailor-made bifunctional ligand systems.
- Author
-
Schibli R, Schwarzbach R, Alberto R, Ortner K, Schmalle H, Dumas C, Egli A, and Schubiger PA
- Subjects
- Cross-Linking Reagents, Crystallography, X-Ray, Drug Stability, Humans, Ligands, Molecular Structure, Organometallic Compounds chemical synthesis, Organometallic Compounds metabolism, Organometallic Compounds therapeutic use, Radioisotopes therapeutic use, Radiopharmaceuticals metabolism, Radiopharmaceuticals therapeutic use, Rhenium, Serum Albumin metabolism, Structure-Activity Relationship, Radiopharmaceuticals chemical synthesis
- Abstract
Two kit preparations of the organometallic precursor [(188)Re(H(2)O)(3)(CO)(3)](+) in aqueous media are presented. Method A uses gaseous carbon monoxide and amine borane (BH(3).NH(3)) as the reducing agent. In method B CO(g) is replaced by K(2)[H(3)BCO(2)] that releases carbon monoxide during hydrolysis. Both procedures afford the desired precursor in yields >85% after 10 min at 60 degrees C. HPLC and TLC analyses revealed 7 +/- 3% of unreacted (188)ReO(4)(-) and <5% of colloidal (188)ReO(2). Solutions of up to 14 GBq/mL Re-188 have been successfully carbonylated with these two methods. The syntheses of two tailor-made bifunctional ligand systems for the precursor [(188)Re(H(2)O)(3)(CO)(3)](+) are presented. The tridentate chelates consist of a bis[imidazol-2-yl]methylamine or an iminodiacetic acid moiety, respectively. Both types of ligand systems have been prepared with alkyl spacers of different length and a pendent primary amino or carboxylic acid functionality, enabling the amidic linkage to biomolecules. The tridentate coordination of the ligands to the rhenium-tricarbonyl core could be elucidated on the macroscopic level by X-ray structure analyses and 1D and 2D NMR experiments of two representative model complexes. On the nca level, the ligands allow labeling yields >95% with [(188)Re(H(2)O)(3)(CO)(3)](+) under mild reaction conditions (PBS buffer, 60 degrees C, 60 min) at ligand concentrations between 5 x 10(-4) M and 5 x 10(-5) M. Thus, specific activities of 22-220 GBq pe micromol of ligand could be achieved. Incubation of the corresponding Re-188 complexes in human serum at 37 degrees C revealed stabilities between 80 +/- 4% and 45 +/- 10% at 24 h, respectively, and 63 +/- 3% and 34 +/- 3% at 48 h postincubation in human serum depending on the chelating system. Decomposition product was mainly (188)ReO(4)(-). The routine kit-preparation of the precursor [(188)Re(H(2)O)(3)(CO)(3)](+) in combination with tailor-made ligand systems enables the organometallic labeling of biomolecules with unprecedented high specific activities.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.